Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ari B. Cuperfain, Gali Katznelson, Tianna Costa, Patrick Wong, Narges Beyraghi, Tony P. George, Michelle R. Lofwall & Nitin Chopra. (2023) Factors to guide the use of extended-release buprenorphine formulations for specific patient populations. Journal of Substance Use 0:0, pages 1-7.
Read now
Read now
Cayley Russell, Michelle Pang, Frishta Nafeh, Shanna Farrell Macdonald, Dena Derkzen, Jürgen Rehm & Benedikt Fischer. (2022) Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada. International Journal of Qualitative Studies on Health and Well-being 17:1.
Read now
Read now
Articles from other publishers (5)
Richard J. Bodnar. (2023) Endogenous opiates and behavior: 2021. Peptides 164, pages 171004.
Crossref
Crossref
Stephanie Paula Elisabeth Guillery, Sven Reiners, Marius Fahrner, Sören Enge, Rainer Hellweg, Hagen Kunte & Golo Kronenberg. (2023) The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients. Addiction Biology 28:5.
Crossref
Crossref
Rosemarie A. Martin, Justin Berk, Josiah D. Rich, Augustine Kang, John Fritsche & Jennifer G. Clarke. (2022) Use of long-acting injectable buprenorphine in the correctional setting. Journal of Substance Abuse Treatment 142, pages 108851.
Crossref
Crossref
Russ Scott, Andrew Aboud & Thomas O’Gorman. (2021) Long-acting injectable buprenorphine – ‘best practice’ opioid agonist therapy for Australian prisoners. Australasian Psychiatry 30:4, pages 498-502.
Crossref
Crossref
Rosemarie A. Martin, Justin Berk, Josiah D. Rich, Augustine Kang, John Fritsche & Jennifer G. Clarke. (2022) Use of Long-Acting Injectable Buprenorphine in the Correctional Setting. SSRN Electronic Journal.
Crossref
Crossref